Barbara Withers
Chief Tech/Sci/R&D Officer at OCUPHIRE PHARMA, INC.
Profile
Barbara Withers is currently working as VP-Clinical & Regulatory Strategy at Ocuphire Pharma, Inc. She has previously worked as Project Director & Site Head at United BioSource Corp., Project Manager-Drug Development at Pfizer Inc., and Vice President-Clinical Operations at Aerpio Pharmaceuticals, Inc. Ms. Withers has an undergraduate degree from the University of Michigan and a doctorate degree from The Wayne State University School of Medicine.
Barbara Withers active positions
| Companies | Position | Start |
|---|---|---|
| OCUPHIRE PHARMA, INC. | Chief Tech/Sci/R&D Officer | - |
Former positions of Barbara Withers
| Companies | Position | End |
|---|---|---|
| PFIZER, INC. | Corporate Officer/Principal | - |
United BioSource Corp.
 United BioSource Corp. Miscellaneous Commercial ServicesCommercial Services United BioSource Corp. is a scientific and medical affairs organization that partners with life science companies to develop and commercialize their products. The company is involved in pre- and post-approval product development; pricing, coverage, reimbursement, and access strategies; and medical publication and communications. United BioSource Corp. was founded by Ethan D. Leder and Mark P. Cleinin in 2003 and is headquartered in Chevy Chase, MD. | Corporate Officer/Principal | - |
| AERPIO PHARMACEUTICALS | Corporate Officer/Principal | - |
Training of Barbara Withers
| The Wayne State University School of Medicine | Doctorate Degree |
| University of Michigan | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| OCUPHIRE PHARMA, INC. | Health Technology |
| PFIZER, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Aerpio Pharmaceuticals, Inc.
 Aerpio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The firm's product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company was founded by Joseph H. Garder on November 16, 2007 and is headquartered in Cincinnati, OH. | Health Technology |
United BioSource Corp.
United BioSource Corp. Miscellaneous Commercial ServicesCommercial Services United BioSource Corp. is a scientific and medical affairs organization that partners with life science companies to develop and commercialize their products. The company is involved in pre- and post-approval product development; pricing, coverage, reimbursement, and access strategies; and medical publication and communications. United BioSource Corp. was founded by Ethan D. Leder and Mark P. Cleinin in 2003 and is headquartered in Chevy Chase, MD. | Commercial Services |
- Stock Market
- Insiders
- Barbara Withers
